Global Bleeding Disorders Treatment Market - Wishtree Insight

Global bleeding disorders treatment Market by Type (Clotting Factor Deficiency, Hemophilia A, Hemophilia B, Von Willebrand Disease (VWD)), Drug Class (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Fibrin Sealant, Antibrinolytics), End-User (Hospitals, Clinics, and Academic institutions), and Regions (The Asia Pacific, Middle East Africa, Europe, North America, and Latin America) - Global Industry Analysis, Share, Growth, Trends, Size, and Forecast 2021 – 2031

The global bleeding disorders treatment market size was valued at USD 15.4 billion in 2021 and is expected to surpass USD 30.1 billion in 2031, expanding at a CAGR of 8.7 % during the forecast period, 2021–2031. The growth of the market is attributed to the increase in blood-related diseases, generic products, awareness, and research & development in bleeding disorders.

INTRODUCTION

A bleeding disorder is a stage in which the clotting function of blood is affected. In the normal human body after any cut or wound blood starts clotting to prevent loss of blood. In case of any injury or wound to the body, blood normally starts to clot to prevent major loss of blood. Bleeding disorders cause bleeding both outside and inside of the body. Some disorders drastically increase blood loss from the body, and some cause bleeding under the skin or in vigorous organs. Blood clotting involves blood components known as ‘platelets. There are 20 different plasma proteins in the body which are known as coagulation factors. These factors interact with other chemicals to form fibrin which helps to stop bleeding. Some bleeding problems are hereditary and are not completely curable. There are three main types of this condition in bleeding disorders, hemophilia (hemophilia A, hemophilia B), clotting factor deficiency, and Von Willebrand Disease (VWD). Treatment of bleeding disorder depends on the type of disorder and its severity. Different treatment options such as replacement therapies that include fresh frozen plasma transfusion, clotting factor replacement, iron supplementation, platelet transfusion, and medication treatments are available for the treatment of bleeding disorder diseases.

Market Trends, Drivers, Restraints, and Opportunities

• The increasing number of disorders and the increase in the number of people being diagnosed with such diseases around the world is the main factor driving the bleeding disorders treatment market.
• Increasing awareness of people about bleeding disorders like hemophilia, anemia, and others is considered a reason for the global growth of this market.
• The rise in generic products and the research & development in this sector is attributed to growing the global bleeding disorder treatment market.
• High government support and initiatives to cultivate a disease-free nation are considered major factors for the rise in the bleeding disorders treatment market.
• Lack of proper treatment and the need for highly skilled experts are restraining the bleeding disorders treatment market.

Scope of the Report

Market Segment Insights

The hemophilia A segment is expected to expand at a rapid pace

Based on type, the global bleeding disorders treatment market is divided into clotting factor deficiency, hemophilia A, hemophilia B, and Von Willebrand Disease (VWD). The hemophilia A segment is expected to expand at a rapid pace during the forecast period. Hemophilia A is the most common type than hemophilia B. The rising R&D investment for hemophilia products, the rise in the number of patients suffering from hemophilia A, and the majority of products used to treat type A hemophilia are considered the key factors to uplift the market.

The plasma-derived segment is projected to register a considerable CAGR

On the basis of drug class, the market is segregated into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, fibrin sealants, and antifibrinolytics. The plasma-derived segment is projected to register a considerable CAGR during the forecast period. It is used to treat bleeds and stop surgical bleeding with von Willebrand disease. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to account for a major market share during the forecast period. The recombinant products provide a safer alternative to plasma-derived coagulation factor concentrates products as they prevent the potential spread of infectious illnesses through blood.

The hospital segment is anticipated to expand at a rapid pace in the coming years

Based on end-user, the global bleeding disorders treatment market is divided into hospitals, clinics, and academic institutions. The hospital segment is anticipated to expand at a rapid pace in the coming years. The growth of the segment is attributed to the availability of certified hematologists, significant quality treatment plans, and increased efficiency in work. The medical facility in hospital benefits patients, hospitals, and insurance companies too. The treatment of bleeding disorder patients is increased in hospitals due to the accessibility of novel remedies.

The North American and Europe region is anticipated to constitute a key market share

In terms of regions, the global bleeding disorders treatment market is classified as the Asia Pacific, Middle East Africa, Europe, North America, and Latin America. The market of the North American and Europe regions is expected to constitute a key share of the market during the projected period due to its highly advanced and well-developed healthcare and research facilities owing to affordability and accessibility to healthcare facilities and increasing awareness about disorders through government and private institutional campaigns. However, the market of the Asia Pacific region is anticipated to expand at a rapid pace during the forecast period with key players adopting an expansion strategy in this region to gain maximum market share. China and India are offering ample opportunities for the growth of the bleeding disorders treatment market with their high population base. Key factors such as increasing government initiatives, and R&D investments are also bleeding disorders treatment markets in the Asia Pacific region.

Competitive Landscape

Key players competing in the global bleeding disorders treatment market are Novo Nordisk (Denmark); Biogen Inc. (U.S.); Grifols SA (Spain); Bayer AG (Germany); Baxter International Inc. (U.S.); Pfizer, Inc. (U.S.); Xenetic Biosciences, Inc. (U.S.); Bristol-Myers Squibb Company (New York); Sanofi (Paris); Amgen, Inc. (California).

FAQs

How much is the market worth?

The global bleeding disorders treatment market size was valued at USD 15.4 billion in 2021 and is expected to surpass USD 30.1 billion in 2031.

Mention the market size of the Global bleeding disorders treatment in 2021.

The market size of the Global bleeding disorders treatment in 2021 was USD 15.4 billion.

During the forecast period, what is the CAGR of the market?

During the forecast period, the CAGR of the market is expected to be 8.7%.

What are the key drivers of the market?

The growth of the market is attributed to the increase in blood-related diseases, generic products, awareness, and research & development in bleeding disorders.

What segments are covered in the Global bleeding disorders treatment report?

The segments covered in the global bleeding disorders treatment report are type (clotting factor deficiency, hemophilia a, hemophilia b, von Willebrand disease (VWD)), drug class (recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, fibrin sealant, antifibrinolytics), end-user (hospitals, clinics, and academic institutions)

Mention the region is expected to hold the highest share in the Global bleeding disorders treatment.

The North American and Europe region is expected to hold the highest share in global bleeding disorders treatment.

Mention the key players in the market.

The key players in the market are Novo Nordisk (Denmark); Biogen Inc. (U.S.); Grifols SA (Spain); Bayer AG (Germany); Baxter International Inc. (U.S.); Pfizer, Inc. (U.S.); Xenetic Biosciences, Inc. (U.S.); Bristol-Myers Squibb Company (New York); Sanofi (Paris); Amgen, Inc. (California).

Which segment dominates the market?

The Hospital segment dominates the market.